Full Text
The Cost Burden of Switching Patients with Relapsing-Remitting Multiple Sclerosis from Glatiramer Acetate To Newly-Approved Disease Modifying Therapies

Abstract

Authors

M. Blackney M. Kelly R. Zeidman M. Andreykiv A. Plich

Back to Volume 17, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×